Genmab A/S’s (GMAB) “Underweight” Rating Reaffirmed at Morgan Stanley

Genmab A/S (NASDAQ:GMAB)‘s stock had its “underweight” rating reissued by Morgan Stanley in a research report issued to clients and investors on Tuesday, March 26th, Benzinga reports.

A number of other equities analysts have also recently issued reports on the stock. Truist Financial reissued a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Tuesday, March 26th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Wednesday, March 6th. BMO Capital Markets upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $46.00 to $48.00 in a research report on Friday, February 23rd. Citigroup downgraded shares of Genmab A/S from a “neutral” rating to a “sell” rating in a research note on Monday, January 22nd. Finally, UBS Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, December 6th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Genmab A/S has a consensus rating of “Hold” and an average price target of $48.50.

Genmab A/S Stock Up 1.2 %

GMAB opened at $30.27 on Tuesday. The business has a 50 day moving average price of $28.96 and a two-hundred day moving average price of $30.89. Genmab A/S has a 52 week low of $26.32 and a 52 week high of $42.99. The company has a market cap of $20.00 billion, a PE ratio of 31.53, a P/E/G ratio of 1.40 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.02. The company had revenue of $675.29 million for the quarter, compared to analyst estimates of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. As a group, sell-side analysts expect that Genmab A/S will post 1.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Alliancebernstein L.P. boosted its holdings in shares of Genmab A/S by 21.0% during the 2nd quarter. Alliancebernstein L.P. now owns 8,187,576 shares of the company’s stock worth $311,210,000 after buying an additional 1,420,915 shares during the period. BlackRock Inc. increased its position in Genmab A/S by 1.6% during the 1st quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock worth $198,799,000 after purchasing an additional 86,571 shares in the last quarter. Capital International Investors increased its position in Genmab A/S by 7.7% during the 1st quarter. Capital International Investors now owns 3,952,446 shares of the company’s stock worth $145,433,000 after purchasing an additional 283,031 shares in the last quarter. Macquarie Group Ltd. increased its position in Genmab A/S by 11.1% during the 1st quarter. Macquarie Group Ltd. now owns 3,484,632 shares of the company’s stock worth $131,580,000 after purchasing an additional 347,437 shares in the last quarter. Finally, Wellington Management Group LLP increased its position in Genmab A/S by 5.8% in the 1st quarter. Wellington Management Group LLP now owns 3,333,824 shares of the company’s stock valued at $120,618,000 after acquiring an additional 183,578 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.